Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 3/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CCNH | P51946 | 1/20 | 0.33 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 2/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035713 | 0.94 | PTK2 (0.37) | FLT3CHEK1IDH2PTK2CCNK | |
| SCHEMBL15041397 | 0.82 | CDK2 (0.35) | FLT3CHEK1CCNKCDK12CDK7 | |
| SCHEMBL15041455 | 0.82 | CDK4 (0.36) | FLT3CCNKCDK12CDK4CDK6 | |
| SCHEMBL15035920 | 0.81 | CDK4 (0.37) | FLT3CCNKCDK12CDK7CCNH | |
| SCHEMBL15035060 | 0.78 | CDK2 (0.37) | FLT3CHEK1PTK2CCNKCDK12 | |
| SCHEMBL15035654 | 0.77 | JAK2 (0.35) | CHEK1IDH2CDK4CDK6CCNE1 | |
| SCHEMBL15242121 | 0.77 | PRKCI (0.40) | CDK4CDK6CDK2 | |
| SCHEMBL15236999 | 0.77 | PRKCI (0.38) | CDK4CDK6CDK2 | |
| SCHEMBL15034956 | 0.76 | IRAK4 (0.35) | FLT3CHEK1PTK2CCNKCDK12 | |
| SCHEMBL15035835 | 0.76 | CDK7 (0.40) | FLT3PTK2CCNKCDK12CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | FLT3 618/4885CHEK1 855/4885IDH2 1104/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | FLT3 811/4885CHEK1 212/4885IDH2 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.